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Available online 22 April 2017The effects of gut microbiota on the central nervous system, along its possible role in mental disorders, have re-
ceived increasing attention. Here we investigated differences in fecal microbiota between 28 patients with first-
episode psychosis (FEP) and 16 healthymatched controls and explored whether such differences were associat-
ed with response after up to 12 months of treatment. Numbers of Lactobacillus group bacteria were elevated in
FEP-patients and significantly correlated with severity along different symptom domains. A subgroup of FEP pa-
tients with the strongestmicrobiota differences also showed poorer response after up to 12months of treatment.
The present findings support the involvement of microbiota alterations in psychotic illness andmay provide the
basis for exploring the benefit of their modulation on treatment response and remission.





The human commensal microbiota plays an important role for the
host physiological, nutritional, and immunological processes (Hooper
et al., 2001). It is involved in the production of short-chain fatty acids
(SCFA) and gases, the transformation of bile acids, the formation of vita-
mins, and the potential formation of mutagenic, toxic, and carcinogenic
substances (O'Hara and Shanahan, 2006). Commensal bacteria are able
to modulate the expression of host genes that regulate diverse and fun-
damental physiological functions. Furthermore, it is being increasingly
recognized that the gut–brain axis provides a bidirectional route of
communication that employs neural, hormonal and immunological
pathways, and that dysfunction of this axis can have pathophysiological
consequences (Collins et al., 2012; Cryan and Dinan, 2012).
Converging evidence suggests that gastrointestinal (GI) inflamma-
tion may have an important role in psychotic disorders (Dinan et al.,. Schwarz).
mark.
niversitaire en santé mentale2014). Autoimmune diseases associated with chronic gastrointestinal
inflammation, like celiac disease, Crohn's disease, and ulcerative colitis,
are associated with increased risk of schizophrenia (Benros et al., 2011)
and mood disorders (Benros et al., 2013). Antibodies to anti-Saccharo-
myces cerevisiae, a marker of GI-inflammation commonly observed in
celiac disease and in Crohn's disease (Shor et al., 2012; Viitasalo et al.,
2014), are elevated in people with first-episode psychosis (FEP),
schizophrenia, and bipolar disorder (Severance et al., 2012; Severance,
Gressitt, et al. 2014). Furthermore, markers of GI-inflammation corre-
latewith serum levels of C-reactive protein (Severance et al., 2013), sug-
gesting that GI-inflammation may contribute to systemic low-level
inflammation, a common feature in psychotic disorders (Bergink et al.,
2014). A contributing factor may also be an increased GI-permeability
(Severance et al., 2016).
The effects of gut microbiota on the central nervous system, along
with its possible role in mental disorders, have received increasing at-
tention in recent years (Borre et al., 2014). Animal studies have shown
that gutmicrobiota influence brain and anxiety- and depression-related
behavior, and the vagus nerve seems to be an important mediator in
these associations (Cryan and Dinan, 2012; Bravo et al., 2011; Bercik
et al., 2011). A link between gut microbiota and autistic-like behaviors
has been supported by animal studies (Hsiao et al., 2013; de Theije et
al., 2014). Similarly, human studies suggest an association with risk of
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vestigated the composition of fecal microbiota of FEP-patients and com-
pare it to healthy matched controls. We also explore whether the
detected compositional differences were associated with symptom se-
verity and remission after 2 months and 1 year of treatment.
2. Methods
2.1. Participants
Patients with first psychotic episode (FEP, 18–40 years), were re-
cruited from the catchment area of the Helsinki University Hospital,
Finland. All primary psychotic disorders were included, substance-in-
duced psychoses and psychotic disorders due to a general medical con-
dition were excluded. The inclusion criterion was a score of at least 4 in
the items assessing delusions (Unusual Thought Content) or hallucina-
tions in the Brief Psychiatric Rating Scale— Extended (BPRS-E) (Ventura
et al., 1993). Controls, matched by age, sex and region of residence,were
identified from the Population Register Center and sent an invitation
letter to participate in the study.
All participants providedwritten informed consent for protocols ap-
proved by the Ethics committee of the Hospital District of Helsinki and
Uusimaa (257/13/03/03/2009). The treating psychiatrist evaluated the
patients' capacity to provide informed consent before they were
approached by the study team.
2.2. Clinical assessment
FEP-patients were assessed three times. The baseline assessment
was conducted when patients entered treatment and was able to give
informed consent. Follow-ups were conducted 2 and 12 months there-
after. Fecal samples were analyzed at baseline only. Clinical information
was utilized from baseline and follow-up to evaluate whether baseline
fecal microbiota composition predicted clinical outcome at follow-ups.
Each assessment point consisted of an interview, questionnaire, and
collection of blood and fecal samples. The severity of psychotic symp-
toms was assessed using the BPRS-E complemented by three domains
(alogia, anhedonia-asociality and avolition-apathy) from the Scale for
the Assessment of Negative Symptoms (SANS) (Andreasen et al.,
2010). For assessing the severity of positive symptoms, we calculated
sum of BPRS items Hallucinations, Unusual thought content, Bizarre be-
havior and Conceptual disorganization; and for assessing the severity of
negative symptoms, we calculated sum of BPRS item Blunted affect and
SANS items Alogia, Anhedonia and Avolition. BPRS items were rescaled
from 1–7 to 0–6 for calculating the sum scores. In addition, the BPRS
total score was used to assess the current (past week) severity of symp-
toms, and the remission criteria by Andreasen et al. (2005) to assess re-
mission at follow-ups (the 6-month duration was not required). Global
Assessment of Functioning (GAF) was used to assess current function-
ing. Structured Clinical Interview for DSM-IV was conducted at 2- and
12-month follow-ups, and for thefinal diagnostic assessment, alsomed-
ical records from all psychiatric treatment contacts were reviewed.
Study interviews were conducted by trained research nurses or psy-
chologists, and all interviewswere reviewed togetherwith a senior psy-
chiatrist (Prof. Jaana Suvisaari) before assigning the DSM-IV diagnosis.
Food habits were assessed by questions adapted from the postal sur-
vey “Health Behavior and Health among the Finnish Adult Population”
(AVTK) (Männistö et al., 2010). Specific questions are shown in Supple-
mentary Table 1.
Physical activity was assessed using the Gothenburg scale (Dinan et
al., 2014). Based on these ratings, we created a dichotomous variable
with “0” indicating all subjects who did not engage in physical activity
during their leisure time and with “1” for physically active subjects.
Patients and controls were assessed for several metabolic parame-
ters. Laboratory methods for their measurement have been described
previously (Keinänen et al., 2015).2.3. Fecal samples
Fresh fecal samples from hospital patients were taken at baseline,
the next morning after the initial interview and stored immediately at
−80 °C. Outpatients visited the laboratorywithin oneweek after the in-
terview and similarly had fresh samples taken in the same morning to
the laboratory for immediate storage at −80 °C Control people also
took the samples at home and delivered them within a few hours to
the laboratory for immediate storage at −80 °C. Fecal samples were
defacated into a larger sampling bowl, from which duplicate samples
(if possible) were further transferred to smaller tubes for storage.
Fecal samples were not collected if the subject reported having any of
the following: antibiotic use during the past 3months, chronic gastroin-
testinal disease, gastrointestinal surgery, or diagnosed celiac disease.
Fecal samples were not collected during follow-up visits.
2.4. Quantitative real-time PCR (qPCR) analyses
DNA extraction was performed from 0.2 g of fecal sample as previ-
ously described (Maukonen et al., 2006). The fecal bacterial numbers
were analyzed by performing seven different bacterial qPCR analyses
for “all” bacteria, Lachnospiraceae (Eubacterium rectale group; Erec),
Ruminococcaceae (Clostridium leptum group; Clept), Bacteroides spp.,
Atopobium group in addition to bifidobacteria and Lactobacillus-group
(comprising of the genera Lactobacillus, Leuconostoc, Pediococcus, and
Weissella) as previously described (Maukonen et al., 2006; Simões et
al., 2013). Briefly, standard curves were obtained from genomic DNA
templates isolated from pure cultures as previously described (Simões
et al., 2013). The extracted DNA was quantified by using NanoDrop
2000c equipment (Thermo Scientific). For each bacterium of interest,
the number of cells present in the volume loaded to the qPCR reaction
was calculated on the basis of the genome size and the respective 16S
ribosomal RNA copy number per cell, identified through the National
Center for Biotechnology Information genome database (http://www.
ncbi.nlm.nih.gov/genome/).
2.5. Metagenomic analyses
Aliquots of 75–100 ng of extracted fecal DNAwere used to generate
paired end libraries using the Nugen Ultralow DRMultiplex System fol-
lowing the manufacturer's instructions (http://info.nugeninc.com/
UGOvationUltralowDRMultiplexSystem1-96.html). The libraries were
purified and run on the Bioanalyzer to confirm size and concentration.
Libraries were then sequenced using the Illumina Hi Seq 2000
generating approximately 200,000,000 paired end reads of 100
nucleotides in length. At least 100,000,000 reads were obtained from
each individual.
Sequence reads were filtered to remove low quality sequences,
resulting in a minimum length of 60 nucleotides. Those with homology
to human sequenceswere removed in 2 stages. Thefirst stage employed
the program Bowtie (http://bowtie-bio.sourceforge.net/index.shtml). A
sliding window approach was used to align a 40 bp subsequence from
the reads to the human genome Build 37 (ftp://ftp.ccb.jhu.edu/pub/
data/bowtie_indexes/hg18.ebwt.zip). During each iteration, readsmap-
ping to the human genome were removed and the subsequence used
for alignmentwas offset by 5 bases. The reads that survived this subtrac-
tion procedurewere then imported into CLC GenomicsWorkbench Ver-
sion 6 (www.clcbio.com) and a second subtraction against the human
genome build 37 and additional sets of human sequences available
from the UCSC Genome Browser (http://genome.ucsc.edu) was per-
formed using the ReferenceMapping algorithm employing global align-
ment with the settings of similarity = 0.4 and length = 0.4. In some
cases duplicate reads were also removed by the use of CLC. The
sequence reads which remained following the removal of the
human sequences were then aligned to the Refseq Bacterial Database
(ftp://ftp.ncbi.nlm.nih.gov/refseq/release/bacteria/), version available
Table 1
Demographic and metabolic characteristics of the investigated cohort (BL: baseline, 2 m:
2 month follow-up, 12 m: 12 months follow-up). Values are shown as mean ± SD.
FEP patients Controls P-value (χ2 or
400 E. Schwarz et al. / Schizophrenia Research 192 (2018) 398–403on 10-30-2012, using the ReadMapping algorithm of the CLC Genomics
Workbench Version 6 and settings of length fraction= 0.8 and similar-
ity = 0.8. Consensus reads generated from these mappings were
retained for further analysis.(n = 28) (n = 16) Mann-Whitney U)
Men/women 16/12 8/8 0.65
Age 25.9 ± 5.5 27.8 ± 6.0 0.25
BMI 23.8 ± 4.3 23.9 ± 3.1 0.50
Schizophrenia (yes/no) 14/14 – –
GAF 35.1 ± 4.7 – –
BPRS positive
symptoms
6.8 ± 3.5 – –
BPRS negative
symptoms at BL
6.0 ± 3.8 – –
BPRS positive
symptoms at 2 m
3.6 ± 4.7 – –
BPRS negative
symptoms at 2 m
6.3 ± 4.1 – –
BPRS positive
symptoms at 12 m
1.6 ± 2.9 – –
BPRS negative
symptoms at 12 m
4.5 ± 4.4 – –
S-hs-CRP mg/l 1.9 ± 2.3 2.3 ± 3.2 0.75
P-glucose mmol/l 4.8 ± 1.7 4.0 ± 0.5 0.15
S-insulin mU/l 20.1 ± 27.9 8.3 ± 4.6 0.22
S-cholesterol mmol/l 4.7 ± 0.8 4.8 ± 1.1 0.71
S-HDL-C mmol/l 1.4 ± 0.3 1.6 ± 0.5 0.48
S-LDL-C mmol/l 2.8 ± 0.8 2.7 ± 0.8 0.66
S-triglycerides mmol/l 1.2 ± 0.8 1.2 ± 1.2 0.84
BMI, body mass index; hs-CRP, high sensitivity C-reactive protein; HDL-C, high density li-
poprotein cholesterol; LDL-C, low density lipoprotein cholesterol; P= plasma, S= serum.2.6. Statistical analysis
To performmetagenomics analysis, we used the linear discriminant
analysis (LDA) effect size (LEfSe) method (http://huttenhower.sph.
harvard.edu/lefse/) for biomarker discovery, which performs a com-
bined assessment of statistical significance and biological relevance.
The method utilizes non-parametric Kruskal-Wallis test to investigate
case-control differences, using a sample-wise normalized matrix of rel-
ative abundances and determines the effect size of a given taxon using
LDA. We performed this analysis using the default settings (alpha =
0.05, effect-size threshold of 2). We used as abundance measure the
length of the consensus sequence created by the sample and the refer-
ence bacterial genome.
To identify potential patient subgroup effects based onmetagenomic
microbial abundance, we use the most significant bacterial families
from the LEfSe method and perform partial least squares regression
analysis on taxon-wise normalized data to the range of abundances
(Milligan and Cooper, 1988). Using the projection on the first two com-
ponents,we identified the patients that showed the strongest difference
in microbiota profiles compared to controls. The patient clusters were
subsequently assessed for differences in clinical scores and frequency
of remission after 2 and 12 months of treatment. This was performed
using logistic regression with age and sex as covariates. All statistical
analyses for metagenomic data were performed using the software
package R (http://cran.r-project.org/).
Differences in sociodemographic and clinical characteristics were
assessedwithWilcoxon Rank sum tests or Fisher's exact tests. Student's
t-test was used for testing group differences in log10 transformed qPCR
derived variables and associationswith patients' symptomswere quan-
tified using Spearman's correlation tests.Fig. 1. Difference in bacterial numbers (log10) as detected with bacterial group specific
qPCR analyses between healthy controls and FEP patients. Bacterial groups that shower
enriched levels in patients are shown in red, whereas those with enriched numbers in
controls are shown in green.3. Results
3.1. Clinical characteristics and qPCR-analyses
The cohort investigated in this study comprised 28 FEP-patients and
16 controls (Table 1),whichdid not differ in terms of age (P=0.25), sex
(P = 0.76) and several metabolic parameters (Table 1). Half of the pa-
tients received a DSM-IV diagnosis of schizophrenia by one-year fol-
low-up, while four had schizophreniform disorder, one schizoaffective
disorder, two bipolar I disorder with psychotic features, one major de-
pressive disorder with psychotic features and six psychotic disorder
not otherwise specified. Olanzapine (n = 10), risperidone (n = 7) and
quetiapine (n = 8) were the most commonly used antipsychotics. The
median duration of antipsychotic treatment at baseline was 20 days
(first quartile 13, third quartile 46). Two patients who had refused anti-
psychotic treatment were antipsychotic-naïve at the baseline
assessment.
The numbers of bacteria within the analyzed bacterial groups were
similar in both patients and controls (Fig. 1). Due to high inter-individ-
ual variation and small study population, the differences between cases
and controls were not statistically significant (Fig. 1). However, bacteri-
al numbers correlated with symptom severity in patients (Table 2).
Such correlations were seen for bacterial numbers in the Lactobacillus
group, Lachnospiraceae, Ruminococcaceae and Bacteroides spp. and for
the predominant bacterial number, and the strongest correlations
were seen for higher level of negative symptoms and poorer function-
ing. Notably, duration of antipsychotic treatment did not correlate sig-
nificantly with bacterial numbers in any of the studied groups.3.2. Metagenomic analysis
Application of the LefSe method identified 5 significant differences
at the family level and 10 significant differences at the genus level. At
the family level, Lactobacillaceae, Halothiobacillaceae, Brucellaceae
and Micrococcineae were increased whereas Veillonellaceae were de-
creased in FEP patients compared to controls. Among genera, we
found statistically significant FEP increases in Lactobacillus, Tropheryma,
Halothiobacillus, Saccharophagus, Ochrobactrum, Deferribacter and
Halorubrum. In contrast, Anabaena, Nitrosospira and Gallionella showed
decreased levels. Fig. 1a–c indicate that Lactobacillaceae were overrep-
resented among the taxa that were most strongly increased in patients.
We found schizophrenia patients to be significantly less physically
active compared to control subjects (P = 0.003, Fisher's exact test).
Since this can impact on microbiota composition, we repeated the
LefSe analysis using only physically active subjects (15 cases, 16 con-
trols). In this smaller subject group,we also identified significant patient
increases in Lactobacillaceae and significant decreases in Veillonellaceae
(Supplementary Fig. 1).
Table 2
Spearman rank order correlations between bacterial numbers and clinical symptoms in first-episode psychosis patients.
Group
BPRS total score Positive symptoms Negative symptoms GAF Duration of antipsychotic treatment
rho (P value) rho (P value) rho (P value) rho (P value) rho (P value)
Lachnospiraceae 0.38 (0.048) 0.15 (0.45) 0.49 (0.008) −0.17 (0.38) 0.07 (0.73)
Ruminococcaceae 0.32 (0.10) 0.17 (0.38) 0.47 (0.011) −0.39 (0.040) −0.03 (0.89)
Bacteroides spp. 0.38 (0.049) 0.34 (0.07) 0.23 (0.25) −0.40 (0.034) −0.17 (0.38)
Coriobacteriaceae 0.27 (0.17) 0.26 (0.18) 0.06 (0.76) −0.13 (0.51) 0.02 (0.91)
Bifidobacteria 0.30 (0.13) 0.22 (0.26) 0.36 (0.06) −0.23 (0.25) 0.21 (0.29)
Lactobacillus group 0.48 (0.009) 0.47 (0.012) 0.37 (0.05) −0.52 (0.004) 0.02 (0.94)
Predominant bacteria 0.35 (0.07) 0.21 (0.28) 0.42 (0.027) −0.42 (0.027) −0.13 (0.50)
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confounders
To investigate associations with clinical symptom severity and re-
mission,we identified patients with the greatest multivariate difference
inmicrobiota composition compared to controls. For this,we performed
partial least squares regression using the five bacterial families that
were identified as showing a significant case-control difference by the
LefSe method. We specifically compared the 18 patients that clustered
outside the distribution of the controls against the remaining patientsFig. 2.Taxonomic differences of fecalmicrobiota between FEPpatients and healthy controls deri
are shown in red, whereas those with enriched levels in controls are shown in green. The brig
observed for individual taxa that passed the LefSe significance threshold. (c) Ratio changes (pa(Fig. 2a). Logistic regression accounting for the effects of age and gender
identified significant associations with negative symptoms and GAF
scores (P = 0.0327 and P = 0.0495, respectively, Fig. 2b and c), but
not with positive symptoms (P = 0.331). (See Fig. 3.)
At 12months follow-up, data for 19 out of 28 patients was available
andwe carried the last observed response forward (including follow-up
assessment at 2months).We found that microbiota clustering at intake
was significantly associated with remission at follow-up (P = 0.014,
logistic regression). Among patients that clustered with controls inved from the LefSemethod. (a) Taxonomic cladogram. Taxawith enriched levels in patients
htness of the respective colors is proportional to the observed effect size. (b) LDA scores
tient levels/control levels) at the family and genus level.
Fig. 3. Partial least squares regression analysis. (a) Scores plot showing the separation of patient and control samples based on the top 5 most significant families identified by the LefSe
method. (b) Boxplots showing differences in GAF and negative symptom BPRS scores at baseline between patients in clusters 1 and 2 (identified from score plot in a).
402 E. Schwarz et al. / Schizophrenia Research 192 (2018) 398–403terms of microbiota composition, 70% showed remission after
12 months, whereas only 28% of patients with “abnormal” microbiota
composition experienced remission. To explore whether symptom se-
verity at baseline was a potential confounder for the associations be-
tween microbiota clustering and remission, for example due to the
fact thatmore severely ill patients that had a differentialmicrobiota pro-
file receivedmore intensive treatment, we included baseline GAF scores
as covariate. However, this did not lead to a substantial decrease in the
association strength between clustering and remission (P = 0.021, lo-
gistic regression). Investigating the 2 month follow-up time-point indi-
vidually showed a trend towards association between microbiota
clustering and remission (P = 0.09, logistic regression).
To exclude confounding, we compared the clustering against other
variables of potential interest and found no associations with physical
activity (P = 0.38), BMI (P = 0.47), type of psychosis (schizophrenia
vs other, P = 0.99), duration of antipsychotic treatment (P = 0.46) or
the distribution of risperidone, quetiapine or olanzapine treatment
(P = 0.99, P = 0.40 and P = 0.70, respectively). Finally, we compared
the microbiota clustering in patients against 15 ratings quantifying the
intake of different food types over the week prior to sample collection
(Supplementary Table 1). This did not identify any significant associa-
tions with the clustering (minimum P-value across 14 comparisons
was 0.07).
4. Discussion
The present analysis identified differences between FEP-patients and
controls in the gut microbial composition and Lactobacillaceae emerged
as one of the families with the strongest alterations. Lactobacillus group
bacterial numbers correlated positively with severity of psychotic symp-
toms and negatively with global assessment of functioning. The in-
creased levels of lactobacilli in FEP patients are consistent with reports
in autistic children (Adams et al., 2011) and with reports showing in-
creased abundance of bacteriophage genome of Lactobacillus phage
phiadh in human oropharyngeal samples of schizophrenia patients
(Yolken et al., 2015).
Besides Lactobacillus group bacteria, Lachnospiraceae, Rumino-
coccaceae, Bacteroides spp. and predominant bacteria correlated nega-
tively with global assessment of functioning. Interestingly, Blautia
spp., Roseburia spp. and Lachnospiraceae incertae sedis, all belonging
to Lachnospiraceae, have been shown to be decreased in major depres-
sive disorder (Jiang et al., 2015). On the other hand, Bacteroides spp.,
Faecalibacterium sp. and Ruminococcus spp. have been shown to be
less abundant in major depressive disorder (Jiang et al., 2015) and de-
creased fractional representation of Faecalibacterium has also beenfound in bipolar disorder (Evans et al., 2017). Likewise we detected a
trend that FEP patients our control group had lower numbers of
Bacteroides spp. and Ruminococcaceae (including Faecalibacterium sp.
and Ruminococcus spp.).
At the family level, relative proportions of Lactobacillaceae,
Halothiobacillaceae, Brucellaceae and Micrococcineae were increased
whereas Veillonellaceae were decreased in our FEP patients compared
to controls. Lower relative proportion of Veillonellaceae has also been
detected in major depressive disorder (Jiang et al., 2015).
We foundworse current global functioning aswell as increased neg-
ative symptom BPRS scores in a patient cluster that showed an abnor-
mal microbiota profile. In addition, within this patient cluster,
remission during follow-up was substantially less frequent compared
to patients with a microbiota profile similar to controls. We did not
find evidence that this effect was due to differences in diet or treatment
ofmore severely ill patients As thefindings are similar to those reported
in MDD and autism, gut microbiota might reflect some dietary pattern,
treatment, or etiological factors shared by several psychiatric disorders,
or other associated characteristics such as obesity. On the other hand, it
may be speculated that a normalization of themicrobiota composition is
a potential protective factor for schizophrenia. Interestingly, in mice, in-
gestion of Lactobacillus rhamnosus decreases anxiety and depression-
like behavior and reduces the stress-induced increase of plasma cortico-
sterone levels (Bravo et al., 2011). However, it should be kept in mind
that probiotic lactobacilli by definition are “live microorganisms which
when administered in adequate amounts confer a health benefit on
the host” (Araya et al., 2002), and they do not usually colonize the GI-
tract, as compared to commensal lactobacilli. Nevertheless, probiotic
usage should be considered as a potential confounder for future
investigations.
The main limitation of the present study is its small sample size.
Therefore, findings should be seen as preliminary and need to be
reproduced in independent samples. As the present microbiota profile
was substantially driven by Lactobacillaceae levels, which have previ-
ously been shown to correlate with the consumed diet (Cuervo et al.,
2014; Zhang et al., 2013; Hooda et al., 2012), dietmay impact on themi-
crobiota composition and, in turn, clinical symptom severity and remis-
sion. Here, we did not identify significant associations of dietary habits
with patient clustering, more detailed dietary data would have been
needed to conclusively exclude bias. Also, it is known from rodent stud-
ies that antipsychotic treatment can impact on microbiota profiles
(Davey et al., 2012). Although the median duration of antipsychotic
treatmentwas only 20 days, all patientswere treated, and therefore, po-
tential bias cannot be excluded in the present study. Furthermore, we
observed a significant difference in physical activity between patients
403E. Schwarz et al. / Schizophrenia Research 192 (2018) 398–403and controls. In a smaller subsample stratified for physical activity,
Lactobacillaceae and Veillonellaceae were still associated with diagno-
sis, but many of the less significant strains from the full cohort could
not be found. While this may partially be influenced by sample size dif-
ference, future studies should pay special attention to careful matching
regarding physical activity.
In conclusion,we identified significant yet preliminary differences in
microbial numbers and composition between FEP patients and controls
that showed associations with symptom severity at baseline and re-
sponse after 12 months of treatment. Further studies are required to
replicate these findings and may provide the basis for exploring the
benefit of microbiotamodulation on treatment response and remission.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2017.04.017.
Author contributions
JM, TK, MO, OM, MS, RY, JS, and ES conceived and designed the experiments. JM, TH,
SS, TK, OM and JS performed the experiments. ES, JM, and JS analyzed the data. ES, JM,
MS, RY, and JS contributed reagents/materials/analysis tools. All authors contributed to
the writing of the manuscript.
Conflict of interests
The authors declare no conflicts of interest.
Role of the funding source
The sponsor had no role in study design; in the collection, analysis and interpretation
of data; in thewriting of the report; or in the decision to submit the paper for publication.
Acknowledgements
This study was supported by Jalmari and Rauha Ahokas Foundation
(TH), Stanley Medical Research Institute (RY and SS, JM), Sigrid Juselius
Foundation (JS), Finnish Cultural Foundation (JS), Helsinki University
Central Hospital (OM), Academy of Finland (Grant # 278171 to JS),
and the Deutsche Forschungsgemeinschaft (DFG) Emmy-Noether-Pro-
gram SCHW1768/1-1 (ES). The funders had no role in study design, da-
ta collection and analysis, decision to publish, or preparation of the
manuscript. Marja-Liisa Jalovaara and Tuula Mononen are greatly ac-
knowledged for their excellent technical assistance.
References
Hooper, L.V., et al., 2001. Molecular analysis of commensal host-microbial relations hips in
the intestine. Science 291 (5505), 881–884.
Adams, J.B., et al., 2011. Gastrointestinal flora and gastrointestinal status in children with
autism—comparisons to typical children and correlation with autism severity. BMC
Gastroenterol. 11, 22.
Andreasen, N.C., et al., 2005. Remission in schizophrenia: proposed criteria and rationale
for consensus. Am. J. Psychiatr. 162 (3), 441–449.
Andreasen, N.C., et al., 2010. Antipsychotic dose equivalents and dose-years: a standard-
ized method for comparing exposure to different drugs. Biol. Psychiatry 67 (3),
255–262.
Araya, M., 2002. Joint FAO/WHO Working Group — Guidelines for the Evaluation of
Probiotics in Food.
Benros, M.E., et al., 2011. Autoimmune diseases and severe infections as risk factors for
schizophrenia: a 30-year population-based register study. Am. J. Psychiatr. 168
(12), 1303–1310.
Benros, M.E., et al., 2013. Autoimmune diseases and severe infections as risk factors for
mood disorders: a nationwide study. JAMA Psychiatry 70 (8), 812–820.
Bercik, P., et al., 2011. The anxiolytic effect of Bifidobacterium longum NCC3001 involves
vagal pathways for gut-brain communication. Neurogastroenterol. Motil. 23 (12),
1132–1139.Bergink, V., Gibney, S.M., Drexhage, H.A., 2014. Autoimmunity, inflammation, and psycho-
sis: a search for peripheral markers. Biol. Psychiatry 75 (4), 324–331.
Borre, Y.E., et al., 2014. Microbiota and neurodevelopmental windows: implications for
brain disorders. Trends Mol. Med. 20 (9), 509–518.
Bravo, J.A., et al., 2011. Ingestion of Lactobacillus strain regulates emotional behavior and
central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad.
Sci. U. S. A. 108 (38), 16050–16055.
Collins, S.M., Surette, M., Bercik, P., 2012. The interplay between the intestinal microbiota
and the brain. Nat. Rev. Microbiol. 10 (11), 735–742.
Cryan, J.F., Dinan, T.G., 2012. Mind-altering microorganisms: the impact of the gut micro-
biota on brain and behaviour. Nat. Rev. Neurosci. 13 (10), 701–712.
Cuervo, A., et al., 2014. Pilot study of diet andmicrobiota: interactive associations of fibers
and polyphenols with human intestinal bacteria. J. Agric. Food Chem. 62 (23),
5330–5336.
Davey, K.J., et al., 2012. Gender-dependent consequences of chronic olanzapine in the rat:
effects on body weight, inflammatory, metabolic and microbiota parameters. Psycho-
pharmacology 221 (1), 155–169.
Dinan, T., Borre, Y., Cryan, J., 2014. Genomics of schizophrenia: time to consider the gut
microbiome? Mol. Psychiatry 19 (12), 1252–1257.
Evans, S.J., et al., 2017. The gut microbiome composition associates with bipolar disorder
and illness severity. J. Psychiatr. Res. 87, 23–29.
Hooda, S., et al., 2012. 454 pyrosequencing reveals a shift in fecal microbiota of healthy
adult men consuming polydextrose or soluble corn fiber. J. Nutr. 142 (7), 1259–1265.
Hsiao, E.Y., et al., 2013. Microbiota modulate behavioral and physiological abnormalities
associated with neurodevelopmental disorders. Cell 155 (7), 1451–1463.
Jiang, H., et al., 2015. Altered fecal microbiota composition in patients with major depres-
sive disorder. Brain Behav. Immun. 48, 186–194.
Keinänen, J., et al., 2015. Early insulin resistance predicts weight gain andwaist circumfer-
ence increase in first-episode psychosis— a one year follow-up study. Schizophr. Res.
169 (1–3), 458–463.
Männistö, S., et al., 2010. Monitoring diet and diet-related chronic disease risk factors in
Finland. Public Health Nutr. 13 (6A), 907–914.
Maukonen, J., et al., 2006. PCR DGGE and RT-PCR DGGE show diversity and short-term
temporal stability in the Clostridium coccoides-Eubacterium rectale group in the
human intestinal microbiota. FEMS Microbiol. Ecol. 58 (3), 517–528.
Milligan, G.W., Cooper, M.C., 1988. A study of standardization of variables in cluster anal-
ysis. J. Classif. 5 (2), 181–204.
O'Hara, A.M., Shanahan, F., 2006. The gut flora as a forgotten organ. EMBO Rep. 7 (7),
688–693.
Severance, E.G., et al., 2012. Gastrointestinal inflammation and associated immune activa-
tion in schizophrenia. Schizophr. Res. 138 (1), 48–53.
Severance, E.G., et al., 2013. Discordant patterns of bacterial translocation markers and
implications for innate immune imbalances in schizophrenia. Schizophr. Res. 148
(1–3), 130–137.
Severance, E.G., Gressitt, K.L., et al., 2014. Seroreactive marker for inflammatory bowel
disease and associations with antibodies to dietary proteins in bipolar disorder. Bipo-
lar Disord. 16 (3), 230–240.
Severance, E.G., Yolken, R.H., Eaton, W.W., 2016. Autoimmune diseases, gastrointestinal
disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr.
Res. 176 (1), 23–35.
Shor, D.B.-A., et al., 2012. Gastrointestinal-associated autoantibodies in different autoim-
mune diseases. Am. J. Clin. Exper. Immunol. 1 (1), 49–55.
Simões, C.D., et al., 2013. Habitual dietary intake is associated with stool microbiota com-
position in monozygotic twins. J. Nutr. 143 (4), 417–423.
de Theije, C.G.M., et al., 2014. Altered gut microbiota and activity in a murine model of au-
tism spectrum disorders. Brain Behav. Immun. 37, 197–206.
Ventura, J., et al., 1993. Brief psychiatric rating scale (BPRS), expanded version (4.0):
scales, anchor points, and administration manual. Int. J. Methods Psychiatr. Res. 3,
227–243.
Viitasalo, L., et al., 2014. Early microbial markers of celiac disease. J. Clin. Gastroenterol. 48
(7), 620–624.
Yolken, R.H., et al., 2015. Metagenomic sequencing indicates that the oropharyngeal
phageome of individuals with schizophrenia differs from that of controls. Schizophr.
Bull. 41 (5), 1153–1161.
Zhang, C., et al., 2013. Structural modulation of gut microbiota in life-long calorie-restrict-
ed mice. Nat. Commun. 4, 2163.
